NEW YORK, Aug. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Every organization has a China strategy, though for many of us it is simply "ignore it." A great opportunity exists in working with China and implementing an effective company strategy. However, winning in Asia in the new millennium will require fundamental changes in partnerships between western and Asian companies. Every company faces the question "What should our China strategy be?" But to neglect China is to forego opportunities to gain efficiency in most of the things we are trying to do. China provides opportunities that allow us to do different things and not just do things differently.
This volume provides an overview of the biopharmaceutical industry, and the state of technology. It will help the reader understand general business practice in China, analyze business opportunities and in identifying potential partners for working in China. It provides a ready reference for all aspects of the world of biopharmaceuticals in China, including general understanding, detailed technical and business descriptions, and detailed information on all types of organizations involved in biopharmaceuticals in China, whether they be companies (state owned or privately owned), universities, or government institutions.
By the Numbers:-46 Internationally Recognized Authors
-23 Peer-Reviewed Chapters
-15 Translated Chapters and Case Studies
-19 Case Studies and China Briefs
-Over 2,000 Index Entries
-Current Listing of over 2,000 Chinese Biopharmaceuticals and Diagnostics (database)
Abstracts Chapter 1: Introduction: A China Biopharmaceuticals Strategy
Chapter 2: An Overview of Biopharmaceutical Developments in China
Chapter 3: China's Healthcare System and the Demand for Biopharmaceutical Products
Chapter 4: China Pharmaceuticals Market Situation 2006
Chapter 5: Biopharmaceutical Strategy in China: An Analysis of Innovation, Financing Policies, Talent, and Strategic Considerations Through 2010 (11th 5-year Plan)
Chapter 6: Biopharmaceuticals in China: A Market, Import/Export, and Financial Review
Chapter 7: Pharmacy and Drug Administration in China
Chapter 8: Regulatory Requirements Applicable to Clinical Trials in China
Chapter 9: FDA Requirements Applicable to Testing and Manufacturing Pharmaceutical Products in China for the U. S. Market
Chapter 10: Protection and Enforcement of Biopharmaceutical Intellectual Property Rights in China - A Rapidly Evolving System
Chapter 11: Biopharmaceutical Industry Venture Capital Investment in Mainland China
Chapter 12: Drug Discovery and Development Partnerships: Outsourcing and Partnering with China
Chapter 13: Doing Business in China
Chapter 14: Current Status and Future Prospect of Biogeneric Companies in China
Chapter 15: Biopharmaceutical Products in China
Chapter 16: Chinese Bioindustry Parks: Evolution and Growth
Chapter 17: Organizations in China involved in Biopharmaceutical Research and Manufacturing
Chapter 18: Life Science and Health Science Education in China
Chapter 19: Biopharmaceutical Research Collaboration between Western and Chinese Life Science Organization: A Guide to Prospective Partnership
Chapter 20: Industrial Technology Developments for Chinese Biopharmaceuticals
Chapter 21: Therapeutic Proteins in China
Chapter 22: Vaccines in China: Status of the Chinese Vaccine Industry
Chapter 23: Biotechnology and Analytical Methods in the Modernization of Traditional Chinese Herbal Medicine
Chapter 24: CHINA Briefs (Miscellaneous Articles)
Arnold & Porter, LLP
Beijing BaiAo Pharmaceutical Co., Ltd.
Beijing WanTai Biological Product Co., Ltd.
Business Monitor International
Chemical Industry Press (China)
China National Center for Biotechnology Development
China National Development and Reform Commission, Chinese Academy of Macroeconomic Research
China National Development and Reform Commission, High-Tech Industry Department
China Pharmaceutical University, College of Life Science and Technology
Chinese Academy of Social Sciences (CASS), Institute of World Economics and Politics
Chinese Ministry of Science and Technology, National Advisory Committee for "863 High Technology Program"
Deacons Hong Kong
Fudan University, International Finance
Nanjing University, Department of Biochemistry
National Institutes of Health (NIH), Office of Technology Transfer
National Vaccine & Serum Institute
Perkins Coie LLP (Los Angeles)
Shanghai CITIC GuoJian Pharmaceutical Co., Ltd.
Shanghai Tongji University, Investment Research Institute
Shanghai Venture Capital Corporation
Shenzhen Neptunus Interlong Biotech Co., Ltd
Shenzhen ZYPH Intelligence Co., Ltd.
Sichuan University, West China School of Pharmacy
Strategic Manufacturing Worldwide, Inc.
TechNova Medical Services
Tsinghua University, School of Medicine
Copyright©2010 PR Newswire.
All rights reserved